QQQ   429.28 (-0.42%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   429.28 (-0.42%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   429.28 (-0.42%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   429.28 (-0.42%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)

Jazz Pharmaceuticals (JAZZ) Stock Price, News & Analysis

$107.60
-1.30 (-1.19%)
(As of 10:58 AM ET)
Today's Range
$107.59
$109.26
50-Day Range
$110.58
$132.77
52-Week Range
$107.59
$146.70
Volume
104,551 shs
Average Volume
607,094 shs
Market Capitalization
$6.78 billion
P/E Ratio
17.58
Dividend Yield
N/A
Price Target
$195.08

Jazz Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.85 Rating Score
Upside/​Downside
81.3% Upside
$195.08 Price Target
Short Interest
Bearish
5.41% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.96
Upright™ Environmental Score
News Sentiment
0.44mentions of Jazz Pharmaceuticals in the last 14 days
Based on 9 Articles This Week
Insider Trading
Acquiring Shares
$1.44 M Bought Last Quarter
Proj. Earnings Growth
14.72%
From $16.24 to $18.63 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.79 out of 5 stars

Medical Sector

38th out of 930 stocks

Pharmaceutical Preparations Industry

14th out of 430 stocks

JAZZ stock logo

About Jazz Pharmaceuticals Stock (NASDAQ:JAZZ)

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

JAZZ Stock Price History

JAZZ Stock News Headlines

This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
Breaking Down Jazz Pharmaceuticals: 15 Analysts Share Their Views
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
Jazz Pharmaceuticals: Cancer and the Combination Approach
Cancer and the Combination Approach
The Analyst Landscape: 12 Takes On Jazz Pharmaceuticals
JAZZ Apr 2024 110.000 put
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
Q4 2023 Zymeworks Inc Earnings Call
See More Headlines
Receive JAZZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/17/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:JAZZ
CUSIP
G5087110
Employees
2,800
Year Founded
2003

Price Target and Rating

Average Stock Price Target
$195.08
High Stock Price Target
$230.00
Low Stock Price Target
$131.00
Potential Upside/Downside
+80.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.85
Research Coverage
13 Analysts

Profitability

Net Income
$414.83 million
Pretax Margin
7.77%

Debt

Sales & Book Value

Annual Sales
$3.83 billion
Cash Flow
$27.11 per share
Book Value
$59.36 per share

Miscellaneous

Free Float
60,228,000
Market Cap
$6.81 billion
Optionable
Optionable
Beta
0.59

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

JAZZ Stock Analysis - Frequently Asked Questions

Should I buy or sell Jazz Pharmaceuticals stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" JAZZ shares.
View JAZZ analyst ratings
or view top-rated stocks.

What is Jazz Pharmaceuticals' stock price target for 2024?

13 Wall Street analysts have issued twelve-month price targets for Jazz Pharmaceuticals' shares. Their JAZZ share price targets range from $131.00 to $230.00. On average, they anticipate the company's share price to reach $195.08 in the next twelve months. This suggests a possible upside of 81.3% from the stock's current price.
View analysts price targets for JAZZ
or view top-rated stocks among Wall Street analysts.

How have JAZZ shares performed in 2024?

Jazz Pharmaceuticals' stock was trading at $123.00 at the start of the year. Since then, JAZZ shares have decreased by 12.5% and is now trading at $107.60.
View the best growth stocks for 2024 here
.

When is Jazz Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our JAZZ earnings forecast
.

How were Jazz Pharmaceuticals' earnings last quarter?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) issued its quarterly earnings results on Wednesday, February, 28th. The specialty pharmaceutical company reported $4.40 earnings per share for the quarter, missing analysts' consensus estimates of $4.44 by $0.04. The specialty pharmaceutical company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1.01 billion. Jazz Pharmaceuticals had a trailing twelve-month return on equity of 31.27% and a net margin of 10.82%.

What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?

Jazz Pharmaceuticals updated its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided EPS guidance of 18.150-19.350 for the period, compared to the consensus earnings per share estimate of 19.940. The company issued revenue guidance of $4.0 billion-$4.2 billion, compared to the consensus revenue estimate of $4.1 billion.

What is Bruce C. Cozadd's approval rating as Jazz Pharmaceuticals' CEO?

60 employees have rated Jazz Pharmaceuticals Chief Executive Officer Bruce C. Cozadd on Glassdoor.com. Bruce C. Cozadd has an approval rating of 92% among the company's employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Jazz Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Bank of America (BAC) and Biogen (biib).

Who are Jazz Pharmaceuticals' major shareholders?

Jazz Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Perpetual Ltd (0.75%), Los Angeles Capital Management LLC (0.32%), Centre Asset Management LLC (0.11%), Alaska Permanent Fund Corp (0.03%), Signet Financial Management LLC (0.02%) and Cardinal Capital Management (0.02%). Insiders that own company stock include Anne Oriordan, Bruce C Cozadd, Bruce C Cozadd, Christopher J Tovey, Elmar Schnee, Finbar Larkin, James E Flynn, Jennifer E Cook, Kenneth W O'keefe, Kim Sablich, Mark Douglas Smith, Neena M Patil, Patricia Carr, Patrick G Enright, Peter Gray, Philip L Johnson, Renee D Gala, Rick E Winningham, Robert Iannone and Samantha Pearce.
View institutional ownership trends
.

How do I buy shares of Jazz Pharmaceuticals?

Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Jazz Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Jazz Pharmaceuticals: Cavion.
Read More
This page (NASDAQ:JAZZ) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners